Tracking Treatment Pathways in Adult Patients With Hyperkalemia.

You may be eligible if

• 1. Age ≥18 years on the date of signing informed consent
• 2. HK with serum potassium (K+) level(s) greater than 5.0 mmol/L, collected during Standard of Care, within 21 days prior to the date of enrollment\*
• 3. Provision of signed and dated informed consent
• (\*enrollment in study is defined as the date of Informed consent and confirmation of study eligibility, whichever occurs later).
• Patients will be excluded from the study if they meet any of the following criteria:
• 1. Concurrent participation in any trial that includes the use of K+ binders as an investigational medicinal product (IMP)
• 2. Patients with pseudohyperkalemia
• 3. A life expectancy of less than six months, based on physician judgement
• 4. Acute causes of HK such as infections and/or trauma to be determined by the principal investigator
• 5. Scheduled renal transplant
• 6. Involvement in the planning and/or conduct of the study